



US005767160A

**United States Patent** [19]  
**Kaesemeyer**

[11] **Patent Number:** **5,767,160**  
 [45] **Date of Patent:** **Jun. 16, 1998**

[54] **METHOD AND FORMULATION OF  
 STIMULATING NITRIC OXIDE SYNTHESIS**

[75] **Inventor:** **W. H. Kaesemeyer**, Augusta, Ga.

[73] **Assignee:** **Notol, Inc.**, Augusta, Ga.

[21] **Appl. No.:** **693,882**

[22] **Filed:** **Aug. 5, 1996**

**Related U.S. Application Data**

[63] **Continuation-in-part of Ser. No. 321,051, Oct. 5, 1994, Pat. No. 5,543,430.**

[51] **Int. Cl.<sup>6</sup>** ..... **A61K 31/195**

[52] **U.S. Cl.** ..... **514/565**

[58] **Field of Search** ..... **514/565**

[56] **References Cited**

**U.S. PATENT DOCUMENTS**

4,686,211 8/1987 Hara et al. .  
 5,059,712 10/1991 Griffith .  
 5,132,407 7/1992 Stuehr et al. .  
 5,132,453 7/1992 Griffith .  
 5,158,883 10/1992 Griffith .  
 5,196,195 3/1993 Griffith .  
 5,266,594 11/1993 Dawson et al. .  
 5,273,875 12/1993 Griffith .  
 5,281,627 1/1994 Griffith .  
 5,286,739 2/1994 Kilbourn et al. .

**OTHER PUBLICATIONS**

Patel, J. M. et al. Nitric Oxide Exposure and Sulfhydryl Modulation Alter L-Arginine Transport in Cultured Pulmonary Artery Endothelial Cells. (Abstract Only) *Free Radical Biology & Medicine*. vol. 20, No. 5. p. 629. 1996.  
 Lee, T. J. F. et al. Inhibition of Cerebral Neurogenic Vasodilation by L-Glutamine and Nitric Oxide Synthase Inhibitors and Its Reversal by L-Citrulline. *The Journal of Pharmacology and Experimental Therapeutics*. vol. 276, No. 2. pp. 353-358. 1996.  
 Horn, M. et al. Preservation of Left Ventricular Mechanical Function and Energy Metabolism in Rats After Myocardial Infarction by the Angiotensin-Converting Enzyme Inhibitor Quinapril. (Abstract Only) *Journal of Cardiovascular Pharmacology*. vol. 27. p.201. 1996.  
 Quigley, R. L. et al. Immediate Hemodynamic Effects of Thrombolytic Therapy on the Ischemic Myocardium. *Catheterization and Cardiovascular Diagnosis*. vol. 38. pp. 325-330. 1996.  
 Abou-Mohamed, G. et al. L-Arginine in the Development and Reversal of Tolerance to Nitroglycerin. (Abstract Only) *FASEB J.* vol. 10, No. 3. p. A569(no.3280) 1996.  
 Edner, M. et al. Effect of Enalapril Initiated Early after Acute Myocardial Infarction on Heart Failure Parameters, with Reference to Clinical Class and Echocardiographic Determinants. *Clin. Cardiol.* vol. 19, pp. 543-548. 1996.  
 Saavedra, J. E. et al. Localizing Antithrombotic and Vasodilatory Activity with a Novel, Ultrafast Nitric Oxide Donor. *Journal of Medicinal Chemistry*. vol. 39, No. 22. pp. 4361-4365. 1996.

Mori, K. et al. Endothelium-Dependent Relaxation of Rat Thoracic Aorta by Amrinone-Induced Nitric Oxide Release. (Abstract Only) *The European Society of Cardiology*. 1996.  
 Schwarzscher, S. P. et al. Local Delivery of L-Arginine Increases Vascular Nitric Oxide Production and Improves Endothelium Dependent Vasomotion. (Abstract Only) *JACC*. No. 779-6. p. 288A Feb. 1996.  
 Fayyaz, M. et al. Antioxidants Are Vasodilators. *JACC*. No. 933-88. p. 130A. Feb. 1996.  
 Daghighi, F. et al. Chemical Modification and Inactivation of Rat Liver Arginase by N-Bromosuccinimide: Reaction with His141. (Abstract Only) *Archives of Biochemistry & Biophysics*. vol. 327. pp. 107-112. Mar. 1. 1996.  
 Xia, Y. et al. Nitric Oxide Synthase Generates Superoxide and Nitric Oxide in Arginine-Depleted Cells Leading to Peroxynitrite-Mediated Cellular Injury. *Proc. Natl. Acad. Sci. USA*. vol. 93. pp. 6770-6774. Jun. 1996.  
 Rector, T. S. et al. Randomized, Double-Blind, Placebo-controlled Study of Supplemental Oral L-Arginine in Patients With Heart Failure. *Circulation*. vol. 93, No. 12. pp. 2135-2141. Jun. 15, 1996.  
 Jeremy, R. W. et al. Effects of Dietary L-Arginine on Atherosclerosis and Endothelium-Dependent Vasodilation in the Hypercholesterolemic Rabbit. *Circulation*. vol. 94, No. 3. pp. 498-506. Aug. 1, 1996.  
 Block, E. R. et al. Hypoxia Inhibits L-Arginine Uptake By Pulmonary Artery Endothelial Cells. (Abstract Only) *Am. J. Physiol.* vol. 269. L574-L580. 1995.  
 Mayer, J. E. et al. Effects of L-Arginine and L-Nitro-Arginine Methyl Ester on Recovery of Neonatal lamb Hearts After Cold Ischemia. (Abstract Only) *J Thoracic Cardiovasc Surg*. vol. 109. pp. 81-87. 1995.  
 Lee, T. J. F. et al. Inhibition of Cerebral Neurogenic Vasodilation by L-Glutamine and Nitric Oxide Synthase Inhibitors and Its Reversal by L-Citrulline. *The Journal of Pharmacology and Experimental Therapeutics*. vol. 276, No. 2. pp. 353-358. 1996.  
 Xabregas, A. et al. Nitric Oxide, L-Arginine, Hypertension and Cardiopulmonary Bypass Three Case Reports. *Applied Cardiopulmonary Pathophysiology*. vol. 5. pp. 231-236. 1995.

(List continued on next page.)

**Primary Examiner**—Paul J. Killos  
**Attorney, Agent, or Firm**—Reed Smith Shaw & McClay;  
 Raymond A. Miller

[57] **ABSTRACT**

A therapeutic in vitro or in vivo mixture comprising L-arginine and an agonist of nitric oxide synthase, namely nitroglycerin is disclosed for the treatment of diseases related to vasoconstriction, wherein the vasoconstriction is relieved by stimulating the constitutive form of nitric oxide synthase (cNOS) to produce native nitric oxide (NO). The native NO having superior beneficial effect when compared to exogenous NO produced by a L-arginine independent pathway in terms of the ability to reduce clinical endpoints and mortality.

**20 Claims, 5 Drawing Sheets**